Changes in blood concentration of nafamostat mesilate during hemodialysis and changes in blood data related to blood coagulation

Evaluation of the pharmacokinetics of the nafamostat mesylate and changes in clotting factors for Continuous renal replacement therapy - Evaluation of the pharmacokinetics of NM for CRRT

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000048844

Enrollment

Registered

2022-09-03

Start date

2014-10-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sepsis, acute kidney injury

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with acute renal failure or chronic renal failure due to severe infection, sepsis, multiple organ failure, acute liver failure, acute pancreatitis, or acute circulatory failure who require CRRT and use nafamostat mesilate as an anticoagulant.

Exclusion criteria

Exclusion criteria: Patients who are pregnant or may be pregnant Patients deemed inappropriate by the attending physician Patients receiving blood products (concentrated red blood cells, fresh frozen plasma, platelets, etc.) during treatment

Design outcomes

Primary

Measure	Time frame
Concentration of nafamostat mesylate in blood for Continuous renal replacement therapy	—

Countries

Japan

Contacts

Public ContactKouji Konishi

Nara Medical University Hospital Medical Technology Center

kk4794@naramed-u.ac.jp0744-22-3051

Outcome results